Pascal Biosciences Inc. (PSCBF) Stock Analysis
DELISTED 2024
What happened to Pascal Biosciences Inc. (PSCBF) stock?
Pascal Biosciences Inc. (PSCBF) no longer trades on public markets. It was delisted in June 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pascal Biosciences Inc. (PSCBF) trades at $0.11. Pascal Biosciences Inc. is a biotechnology company focused on developing therapies for cancer and immune system improvement. Market cap: $4.20M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for PSCBF: PSCBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PSCBF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PSCBF: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Pascal Biosciences Inc. (PSCBF) Healthcare & Pipeline Overview
Pascal Biosciences Inc. is a biotechnology company developing innovative therapies for cancer and immune-related diseases. Their pipeline includes PAS-403, a mitosis inhibitor for brain cancer, and PAS-393, an immune-stimulatory cannabinoid. The company operates in the competitive biotechnology sector, focusing on unmet medical needs.
What Is the Investment Thesis for PSCBF?
Pascal Biosciences Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on novel cancer therapies, particularly PAS-403 and PAS-393, addresses significant unmet medical needs. Successful clinical development and commercialization of these assets could drive substantial value. The collaboration with SoRSE Technology Corporation to advance PAS-393 into clinical testing is a key catalyst. However, the company's small market capitalization ($0.00B), negative P/E ratio (-5.13), and reliance on future funding pose significant risks. Investors should carefully consider the inherent uncertainties and potential for dilution associated with early-stage biotechnology companies.
Based on FMP financials and quantitative analysis
PSCBF Key Highlights
Pascal Biosciences Inc. is focused on developing therapies for cancer and immune system improvement.
- The company's development portfolio includes PAS-403, a mitosis inhibitor for glioblastoma and brain metastases.
- PAS-393, an immune-stimulatory cannabinoid, is being developed to restore the immunogenicity of tumor cells.
- Pascal Biosciences has an exclusive license agreement with the University of Washington for cannabinoid-based products.
- The company has a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing.
Who Are PSCBF's Competitors?
PSCBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSCBF's Key Strengths?
Novel therapeutic candidates (PAS-403, PAS-393).
- Exclusive license agreement with the University of Washington.
- Collaborative research agreement with SoRSE Technology Corporation.
- Focus on unmet medical needs in cancer and immune-related diseases.
What Are PSCBF's Weaknesses?
Limited financial resources and reliance on future funding.
- Small team and limited infrastructure.
- Early-stage development programs with high risk of failure.
- Dependence on regulatory approvals for commercialization.
What Could Drive PSCBF Stock Higher?
Clinical trial initiation for PAS-403 in glioblastoma.
- Advancement of PAS-393 into clinical testing through collaboration with SoRSE Technology Corporation.
- Development of a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.
- Research and development of cannabinoid therapeutic products for the treatment of COVID-19.
What Are the Key Risks for PSCBF?
Financial-distress signal — its Altman Z-Score of -5.71 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for PAS-403 or PAS-393.
- Regulatory delays or rejection of therapeutic candidates.
- Limited financial resources and reliance on future funding.
- Competition from larger pharmaceutical and biotechnology companies.
- Intellectual property disputes or challenges to patent protection.
What Are the Growth Opportunities for PSCBF?
- Growth opportunity 1: Clinical Development of PAS-403: Pascal Biosciences has the opportunity to advance PAS-403, a mitosis inhibitor, through clinical trials for the treatment of glioblastoma and brain metastases. The timeline for clinical development is typically several years, with regulatory approval contingent on positive trial results. Success in this area would validate the company's technology and attract potential partnerships or acquisitions.
- Growth opportunity 2: Advancement of PAS-393 with Checkpoint Inhibitor Therapy: The development of PAS-393, an immune-stimulatory cannabinoid, presents a growth opportunity for Pascal Biosciences. By restoring the immunogenicity of tumor cells, PAS-393 could enhance the effectiveness of checkpoint inhibitor therapy in cancer treatment. The market for checkpoint inhibitors is substantial, and a successful combination therapy could capture a significant share. The collaborative research agreement with SoRSE Technology Corporation is crucial for advancing PAS-393 into clinical testing. This represents a potential near-term catalyst for the company.
- Growth opportunity 3: Expansion of Cannabinoid Therapeutic Products for COVID-19: Pascal Biosciences is exploring the development of cannabinoid therapeutic products for the treatment of COVID-19. While the pandemic's trajectory is uncertain, there remains a need for effective treatments to mitigate the virus's effects. The company's research in this area could lead to the development of novel therapies that address the inflammatory and immune-related complications of COVID-19. Success in this area would diversify the company's pipeline and provide a new revenue stream.
- Growth opportunity 4: Development of B-Cell Targeted Antibody for Leukemia and Lymphomas: Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. These hematological malignancies represent a significant unmet medical need, and a successful antibody therapy could provide a valuable treatment option. The market for B-cell lymphoma therapies is substantial, with ongoing research focused on improving patient outcomes. Advancement of this program through preclinical and clinical development is a key growth opportunity for the company.
- Growth opportunity 5: Strategic Partnerships and Licensing Agreements: Pascal Biosciences can pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its therapeutic candidates. Collaborating with larger pharmaceutical companies or biotechnology firms can provide access to funding, expertise, and distribution networks. Licensing agreements can generate upfront payments, milestone payments, and royalties, providing a valuable source of revenue. The company's exclusive license agreement with the University of Washington demonstrates its ability to secure valuable intellectual property.
What Threats Does PSCBF Face?
- Competition from larger pharmaceutical and biotechnology companies.
- Regulatory hurdles and delays in approval processes.
- Clinical trial failures and unexpected safety issues.
- Changes in the regulatory landscape for cannabinoid-based therapies.
What Are PSCBF's Competitive Advantages?
- Proprietary technology and intellectual property related to PAS-403 and PAS-393.
- Exclusive license agreement with the University of Washington.
- Collaborative research agreement with SoRSE Technology Corporation.
- First-mover advantage in developing cannabinoid-based therapies for specific indications.
What Does PSCBF Do?
Pascal Biosciences Inc., incorporated in 2011 and headquartered in Seattle, Washington, is a biotechnology company dedicated to the research and development of innovative therapies for cancer and immune system modulation. The company's core focus lies in addressing unmet medical needs through the development of novel therapeutic candidates. Pascal Biosciences' lead development programs include PAS-403, a mitosis inhibitor designed to block cell division in glioblastoma and brain metastases originating from other cancers. Additionally, the company is developing PAS-393, an immune-stimulatory cannabinoid intended to restore the immunogenicity of tumor cells, enhancing the effectiveness of checkpoint inhibitor therapy in cancer treatment. Beyond these lead programs, Pascal Biosciences is also engaged in the development of a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas, as well as cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases. Furthermore, Pascal Biosciences has a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. With a small team of 2 employees, Pascal Biosciences operates in the highly competitive biotechnology landscape, striving to translate innovative research into effective therapies for patients.
What Products and Services Does PSCBF Offer?
- Researches and develops products for cancer treatment.
- Develops products for the improvement of the immune system.
- Develops PAS-403, a mitosis inhibitor for glioblastoma and brain metastases.
- Develops PAS-393, an immune-stimulatory cannabinoid for cancer treatment.
- Develops a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.
- Develops cannabinoid therapeutic products for the treatment of COVID-19.
How Does PSCBF Make Money?
- Research and development of novel therapeutic candidates.
- Securing exclusive licenses and collaborative research agreements.
- Out-licensing or partnering for commercialization of developed products.
- Seeking funding through grants, equity financing, and partnerships.
What Industry Does PSCBF Operate In?
Pascal Biosciences Inc. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increasing incidence rates. Companies like Pascal Biosciences are focused on developing novel approaches to cancer treatment, including immunotherapies and targeted therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in this lucrative sector. The company's focus on cannabinoid-based therapies differentiates it from some competitors.
Who Are PSCBF's Key Customers?
- Pharmaceutical companies (potential partners or licensees).
- Patients suffering from cancer and immune-related diseases.
- Healthcare providers (oncologists, immunologists).
- Research institutions (collaborative partners).
Company Profile
Pascal Biosciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO John Kueber. PSCBF has traded publicly since 2015.
How Pascal Biosciences Inc. Is Valued
Pascal Biosciences Inc. carries a market capitalization of $4.20M, placing it in the micro-cap category.
Key Financial Metrics
Return on assets is -16.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.79 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -11.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Pascal Biosciences Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.71 places it in the distress zone, a signal of elevated financial risk.
PSCBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Pascal Biosciences has seen increased chatter in social trading communities about potential breakthroughs in their cannabinoid-based therapies, suggesting growing investor interest.
- Recent insider buying activity, if confirmed, could signal confidence in the company's future prospects and pipeline.
- The overall market sentiment appears to be cautiously optimistic about biotech companies focusing on novel therapeutic approaches, which may benefit Pascal Biosciences.
- Positive community sentiment highlights the potential of their ImmunoBiotic platform in addressing unmet medical needs.
Bear Case
- Skeptics in the trading community question the scalability and commercial viability of Pascal Biosciences' cannabinoid-based therapies.
- Some investors express concerns about the company's cash burn rate and the need for future funding rounds, potentially leading to dilution.
- Negative community sentiment points to a lack of substantial news or catalysts in the last month, raising doubts about short-term growth.
- The market is sensitive to regulatory hurdles and clinical trial outcomes, which could significantly impact Pascal Biosciences' future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PSCBF Latest News
No recent news available for PSCBF.
Leadership: John Kueber
CEO
Information about John Kueber's background is not available in the provided data. Therefore, a detailed biography cannot be provided. Further research would be needed to determine his career history, education, previous roles, and credentials.
Track Record: Information about John Kueber's track record is not available in the provided data. Therefore, key achievements, strategic decisions, and company milestones under his leadership cannot be assessed. Further research would be needed to evaluate his performance as CEO.
PSCBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pascal Biosciences Inc. may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the potential for fraud, manipulation, and lack of transparency. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for fraud and market manipulation.
- Low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Increased risk of delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has an exclusive license agreement with the University of Washington.
- The company has a collaborative research agreement with SoRSE Technology Corporation.
- The company is focused on developing therapies for cancer and immune-related diseases.
- The company was incorporated in 2011.
PSCBF Healthcare Stock FAQ
What happened to Pascal Biosciences Inc. (PSCBF) stock?
Pascal Biosciences Inc. (PSCBF) no longer trades on public markets. It was delisted in June 2024. The figures below are historical and are not a current quote.
Can I still buy PSCBF shares?
No. PSCBF stopped trading on public markets in June 2024, so the shares are not available through a broker. Anything you see quoted for PSCBF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PSCBF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Pascal Biosciences Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Pascal Biosciences Inc. do?
Pascal Biosciences Inc. is a biotechnology company focused on the research and development of innovative therapies for cancer and immune-related diseases. Their primary focus is on developing PAS-403, a mitosis inhibitor for glioblastoma, and PAS-393, an immune-stimulatory cannabinoid designed to enhance the effectiveness of checkpoint inhibitor therapy.
What do analysts say about PSCBF stock?
There is currently no available analyst coverage or consensus estimates for Pascal Biosciences Inc. (PSCBF) due to its OTC listing and small market capitalization. The company's valuation is difficult to assess based on traditional metrics, given its negative P/E ratio and early-stage development programs.
What are the main risks for PSCBF?
Pascal Biosciences Inc. faces several significant risks, typical of early-stage biotechnology companies. These include the risk of clinical trial failures for its lead therapeutic candidates, PAS-403 and PAS-393. Regulatory delays or rejection of these candidates also pose a substantial risk. The company's limited financial resources and reliance on future funding create financial vulnerability.
How does Pascal Biosciences Inc. navigate regulatory approval processes?
Pascal Biosciences Inc. operates in the healthcare sector, specifically within biotechnology. Revenue streams for such companies typically involve a combination of research grants, licensing agreements, and eventual product sales. As Pascal Biosciences is still in the early stages of development, it currently does not have revenue from product sales.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to the provided source data.
- Analyst consensus and detailed financial analysis are unavailable for this OTC-listed company.
- CEO background and track record require further research.